YY1 and acute myeloid leukemia: Treatment with an HDAC inhibitor treatment significantly reduces the binding of YY1 to HDAC 1/3, resulting in an excessive LLPS state, thereby reducing the expression of METTL3 and the proliferation of acute myeloid leukemia cells 130.